NCT07240142

Neurotransmitter Levels in Children With Specific Learning Disorder

Biochemical and Docking Evidence of Neurotransmitter Dysregulation in Specific Learning Disorder

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Dilara Ulger Ozbek · Academic / Other
• Sex: All
• Age: 7 Years – 14 Years
• Healthy volunteers: Accepted

Summary

The aim of this clinical trial was to measure how specific neurotransmitter levels in children with Specific Learning Disorder (SLD) change compared to controls. The relationship between these markers and the measured markers will be determined both theoretically and experimentally using various neuropsychological tests. The fundamental questions it aims to answer are Did neurotransmitter levels increase or decrease in the patient group? Are the neurotransmitter levels measured in the neuropsychological tests related? Can the measured neurotransmitters be used to predict the disease? Participants: A single visit to the clinic, a blood sample, and neuropsychological tests will be administered on the same day.

Detailed description

The purpose of this investigation was to assess the levels in serum of key neurotransmitters and their precursors (glutamate, L-arginine, and nitric oxide) in children with SLD and also to integrate these biochemical results with molecular docking analyses of their interactions with phospholipase A2 (PLA2) and N-methyl D-aspartate receptors (NMDA), both of which play significant roles in learning function in these patients. The research group consisted of 20 children aged 7-14 years who had been diagnosed with SLD using DSM-5 criteria, as well as 20 age-matched, gender-matched, and educationally matched healthy controls. The children in the study group underwent the Stroop Test \[Total Error Scores, Total Time Scores, Total Correction\] and the Wechsler Intelligence Scale for Children (WISC-IV) subtests, and the results were scored. The serum concentrations of glutamate, L-arginine, and nitric oxide (NO) were determined using ELISA. The diagnostic ability of the biomarkers was evaluated using ROC analysis. Additionally, the interactions of glutamate and L-arginine with the PLA2 enzyme and the NMDA receptor were examined using molecular docking analysis.

Conditions

• Specific Learning Disability
• Healthy (Controls)

Interventions

Type	Name	Description
PROCEDURE	Blood Product	Collecting 5 ml blood samples from the left atrial vein, after that obtaining serum from it.
OTHER	Elisa test	Measurement of glutamate, nitric oxide, and L-arginine concentrations in the blood samples obtained using an ELISA test kit.

Timeline

• Start date: 2019-10-22
• Primary completion: 2020-10-21
• Completion: 2021-04-16
• First posted: 2025-11-20
• Last updated: 2025-11-20

Locations

1 site across 1 country: Turkey (Türkiye)